



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: 普拉克索杂质 D

产品别名: **Dexpramipexole dihydrochloride**; 右旋普拉克索二盐酸盐

生物活性:				
Description	Dexpramipexole dihydrochloride ((R)-Pramipexole dihydrochloride) is a neuroprotective agent and weak non-ergoline dopamine agonist.			
In Vitro	Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and $\beta$ -amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.			
Solvent&Solubility	<b>In Vitro:</b> <b>DMSO : <math>\geq 28</math> mg/mL (98.50 mM)</b>  * "≥" means soluble, but saturation unknown.			
	<div>Preparing Stock Solutions</div>	<div>Solvent Mass Concentration</div>	1 mg	5 mg
		1 mM	3.5180 mL	17.5902 mL
		5 mM	0.7036 mL	3.5180 mL
		10 mM	0.3518 mL	1.7590 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。  储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。			
References	<p>[1]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. <i>Amyotroph Lateral Scler Frontotemporal Degener</i>. 2013 Jan;14(1):44-51.</p> <p>[2]. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. <i>Brain Res</i>. 2012 Mar 29;1446:1-11.</p> <p>[3]. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. <i>Nat Med</i>. 2011 Nov 20;17(12):1652-6.</p> <p>[4]. Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. <i>J Clin Pharmacol</i>. 2011 Aug;51(8):1177-85.</p> <p>[5]. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. <i>IDrugs</i>. 2010 Dec;13(12):911-20.</p>			